{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:26:43Z","timestamp":1793230003401,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T00:00:00Z","timestamp":1518566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T00:00:00Z","timestamp":1518566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Irritable bowel syndrome (IBS) is a common disorder in gastrointestinal system and impairs the quality of life of the patients.\n                    <jats:italic>Clostridium butyricum<\/jats:italic>\n                    (\n                    <jats:italic>CB<\/jats:italic>\n                    ) is a probiotics that has been used in several gastrointestinal diseases. The efficacy of\n                    <jats:italic>CB<\/jats:italic>\n                    in treating IBS is still unknown. This prospective, multi-centre, randomized, double-blind, placebo-controlled trial aimed to assess the efficacy and safety of\n                    <jats:italic>CB<\/jats:italic>\n                    in treating diarrhea-predominant IBS (IBS-D) and analyze the fecal microbiota after treatment. Two hundred patients with IBS-D were recruited and were given\n                    <jats:italic>CB<\/jats:italic>\n                    or placebo for 4 weeks. End points included change from baseline in IBS symptoms, quality of life, stool consistency and frequency. Compared with placebo,\n                    <jats:italic>CB<\/jats:italic>\n                    is effective in improving the overall IBS-D symptoms (\u221262.12\u2009\u00b1\u200974.00 vs. \u221240.74\u2009\u00b1\u200963.67,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.038) as well as quality of life (7.232\u2009\u00b1\u200914.06 vs. 3.159\u2009\u00b1\u200911.73,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.032) and stool frequency (\u22121.602\u2009\u00b1\u20091.416 vs. \u22121.086\u2009\u00b1\u20091.644,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.035). The responder rates are found higher in\n                    <jats:italic>CB<\/jats:italic>\n                    compared with the placebo (44.76% vs. 30.53%,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.042). The change in fecal microbiota was analyzed and function pathways of\n                    <jats:italic>CB<\/jats:italic>\n                    in treating IBS-D were predicted. In conclusion,\n                    <jats:italic>CB<\/jats:italic>\n                    improves overall symptoms, quality of life and stool frequency in IBS-D patients and is considered to be used as a probiotics in treating IBS-D clinically.\n                  <\/jats:p>","DOI":"10.1038\/s41598-018-21241-z","type":"journal-article","created":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T04:46:37Z","timestamp":1518065197000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":108,"title":["The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial"],"prefix":"10.1038","volume":"8","author":[{"given":"Yi-Yuan","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Zhe","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Xiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Jin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Li","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,14]]},"reference":[{"key":"21241_CR1","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","volume":"130","author":"GF Longstreth","year":"2006","unstructured":"Longstreth, G. F. et al. Functional bowel disorders. Gastroenterology 130, 1480\u20131491, https:\/\/doi.org\/10.1053\/j.gastro.2005.11.061 (2006).","journal-title":"Gastroenterology"},{"key":"21241_CR2","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/j.1365-2036.2011.04633.x","volume":"33","author":"S Guglielmetti","year":"2011","unstructured":"Guglielmetti, S., Mora, D., Gschwender, M. & Popp, K. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life\u2013a double-blind, placebo-controlled study. Alimentary pharmacology & therapeutics 33, 1123\u20131132, https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04633.x (2011).","journal-title":"Alimentary pharmacology & therapeutics"},{"key":"21241_CR3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/MCG.0b013e31823712b1","volume":"46","author":"B Ki Cha","year":"2012","unstructured":"Ki Cha, B. et al. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. Journal of clinical gastroenterology 46, 220\u2013227, https:\/\/doi.org\/10.1097\/MCG.0b013e31823712b1 (2012).","journal-title":"Journal of clinical gastroenterology"},{"issue":"Suppl 1","key":"21241_CR4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/ajg.2008.122","volume":"104","author":"American College of Gastroenterology Task Force on Irritable Bowel, S.","year":"2009","unstructured":"American College of Gastroenterology Task Force on Irritable Bowel, S. et al. An evidence-based position statement on the management of irritable bowel syndrome. The American journal of gastroenterology 104(Suppl 1), S1\u201335, https:\/\/doi.org\/10.1038\/ajg.2008.122 (2009).","journal-title":"The American journal of gastroenterology"},{"key":"21241_CR5","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1111\/j.1440-1746.2010.06353.x","volume":"25","author":"KA Gwee","year":"2010","unstructured":"Gwee, K. A. et al. Asian consensus on irritable bowel syndrome. Journal of gastroenterology and hepatology 25, 1189\u20131205, https:\/\/doi.org\/10.1111\/j.1440-1746.2010.06353.x (2010).","journal-title":"Journal of gastroenterology and hepatology"},{"key":"21241_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.giec.2008.12.004","volume":"19","author":"Y Ringel","year":"2009","unstructured":"Ringel, Y. & Carroll, I. M. Alterations in the intestinal microbiota and functional bowel symptoms. Gastrointestinal endoscopy clinics of North America 19, 141\u2013150, https:\/\/doi.org\/10.1016\/j.giec.2008.12.004 (2009). vii.","journal-title":"Gastrointestinal endoscopy clinics of North America"},{"key":"21241_CR7","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1136\/gutjnl-2011-301501","volume":"61","author":"IB Jeffery","year":"2012","unstructured":"Jeffery, I. B. et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 61, 997\u20131006, https:\/\/doi.org\/10.1136\/gutjnl-2011-301501 (2012).","journal-title":"Gut"},{"key":"21241_CR8","doi-asserted-by":"publisher","first-page":"G799","DOI":"10.1152\/ajpgi.00154.2011","volume":"301","author":"IM Carroll","year":"2011","unstructured":"Carroll, I. M. et al. Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. American journal of physiology. Gastrointestinal and liver physiology 301, G799\u2013807, https:\/\/doi.org\/10.1152\/ajpgi.00154.2011 (2011).","journal-title":"American journal of physiology. Gastrointestinal and liver physiology"},{"key":"21241_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.bpg.2016.01.003","volume":"30","author":"K Hod","year":"2016","unstructured":"Hod, K. & Ringel, Y. Probiotics in functional bowel disorders. Best practice & research. Clinical gastroenterology 30, 89\u201397, https:\/\/doi.org\/10.1016\/j.bpg.2016.01.003 (2016).","journal-title":"Clinical gastroenterology"},{"key":"21241_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-016-0470-z","volume":"16","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y. et al. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC gastroenterology 16, 62, https:\/\/doi.org\/10.1186\/s12876-016-0470-z (2016).","journal-title":"BMC gastroenterology"},{"key":"21241_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/apt.12787","volume":"40","author":"G Sisson","year":"2014","unstructured":"Sisson, G., Ayis, S., Sherwood, R. A. & Bjarnason, I. Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome\u2013a 12 week double-blind study. Alimentary pharmacology & therapeutics 40, 51\u201362, https:\/\/doi.org\/10.1111\/apt.12787 (2014).","journal-title":"Alimentary pharmacology & therapeutics"},{"key":"21241_CR12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/2050640615602571","volume":"4","author":"R Spiller","year":"2016","unstructured":"Spiller, R. et al. Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation. United European gastroenterology journal 4, 353\u2013362, https:\/\/doi.org\/10.1177\/2050640615602571 (2016).","journal-title":"United European gastroenterology journal"},{"key":"21241_CR13","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/j.1365-2036.2008.03818.x","volume":"28","author":"J Zeng","year":"2008","unstructured":"Zeng, J. et al. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. Alimentary pharmacology & therapeutics 28, 994\u20131002, https:\/\/doi.org\/10.1111\/j.1365-2036.2008.03818.x (2008).","journal-title":"Alimentary pharmacology & therapeutics"},{"key":"21241_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nm1521","volume":"13","author":"C Rousseaux","year":"2007","unstructured":"Rousseaux, C. et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nature medicine 13, 35\u201337, https:\/\/doi.org\/10.1038\/nm1521 (2007).","journal-title":"Nature medicine"},{"key":"21241_CR15","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1096\/fj.09-153841","volume":"24","author":"B Wang","year":"2010","unstructured":"Wang, B. et al. Luminal administration ex vivo of a live Lactobacillus species moderates mouse jejunal motility within minutes. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 24, 4078\u20134088, https:\/\/doi.org\/10.1096\/fj.09-153841 (2010).","journal-title":"FASEB journal: official publication of the Federation of American Societies for Experimental Biology"},{"key":"21241_CR16","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1053\/j.gastro.2004.11.050","volume":"128","author":"L O\u2019Mahony","year":"2005","unstructured":"O\u2019Mahony, L. et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology 128, 541\u2013551, https:\/\/doi.org\/10.1053\/j.gastro.2004.11.050 (2005).","journal-title":"Gastroenterology"},{"key":"21241_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13099-015-0055-3","volume":"7","author":"S Mo","year":"2015","unstructured":"Mo, S. et al. Genome sequencing of Clostridium butyricum DKU-01, isolated from infant feces. Gut pathogens 7, 8, https:\/\/doi.org\/10.1186\/s13099-015-0055-3 (2015).","journal-title":"Gut pathogens"},{"key":"21241_CR18","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s00595-015-1261-9","volume":"46","author":"A Yasueda","year":"2016","unstructured":"Yasueda, A. et al. The effect of Clostridium butyricum MIYAIRI on the prevention of pouchitis and alteration of the microbiota profile in patients with ulcerative colitis. Surgery today 46, 939\u2013949, https:\/\/doi.org\/10.1007\/s00595-015-1261-9 (2016).","journal-title":"Surgery today"},{"key":"21241_CR19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1046\/j.1442-200X.2003.01671.x","volume":"45","author":"H Seki","year":"2003","unstructured":"Seki, H. et al. Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI. Pediatrics international: official journal of the Japan Pediatric Society 45, 86\u201390 (2003).","journal-title":"Pediatrics international: official journal of the Japan Pediatric Society"},{"key":"21241_CR20","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1046\/j.1365-2036.1997.142318000.x","volume":"11","author":"CY Francis","year":"1997","unstructured":"Francis, C. Y., Morris, J. & Whorwell, P. J. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Alimentary pharmacology & therapeutics 11, 395\u2013402 (1997).","journal-title":"Alimentary pharmacology & therapeutics"},{"key":"21241_CR21","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1023\/A:1018831127942","volume":"43","author":"DL Patrick","year":"1998","unstructured":"Patrick, D. L., Drossman, D. A., Frederick, I. O., DiCesare, J. & Puder, K. L. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Digestive diseases and sciences 43, 400\u2013411 (1998).","journal-title":"Digestive diseases and sciences"},{"key":"21241_CR22","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3109\/00365529709011203","volume":"32","author":"SJ Lewis","year":"1997","unstructured":"Lewis, S. J. & Heaton, K. W. Stool form scale as a useful guide to intestinal transit time. Scandinavian journal of gastroenterology 32, 920\u2013924, https:\/\/doi.org\/10.3109\/00365529709011203 (1997).","journal-title":"Scandinavian journal of gastroenterology"},{"key":"21241_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/srep21952","volume":"6","author":"AH Wang","year":"2016","unstructured":"Wang, A. H. et al. Human colorectal mucosal microbiota correlates with its host niche physiology revealed by endomicroscopy. Scientific reports 6, 21952, https:\/\/doi.org\/10.1038\/srep21952 (2016).","journal-title":"Scientific reports"},{"key":"21241_CR24","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.clnu.2005.06.001","volume":"24","author":"E Niv","year":"2005","unstructured":"Niv, E., Naftali, T., Hallak, R. & Vaisman, N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome\u2013a double blind, placebo-controlled, randomized study. Clinical nutrition 24, 925\u2013931, https:\/\/doi.org\/10.1016\/j.clnu.2005.06.001 (2005).","journal-title":"Clinical nutrition"},{"key":"21241_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.immuni.2015.06.010","volume":"43","author":"I Kashiwagi","year":"2015","unstructured":"Kashiwagi, I. et al. Smad2 and Smad3 Inversely Regulate TGF-beta Autoinduction in Clostridium butyricum-Activated Dendritic Cells. Immunity 43, 65\u201379, https:\/\/doi.org\/10.1016\/j.immuni.2015.06.010 (2015).","journal-title":"Immunity"},{"key":"21241_CR26","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.chom.2013.05.013","volume":"13","author":"A Hayashi","year":"2013","unstructured":"Hayashi, A. et al. A single strain of Clostridium butyricum induces intestinal IL-10-producing macrophages to suppress acute experimental colitis in mice. Cell host & microbe 13, 711\u2013722, https:\/\/doi.org\/10.1016\/j.chom.2013.05.013 (2013).","journal-title":"Cell host & microbe"},{"key":"21241_CR27","doi-asserted-by":"publisher","unstructured":"Tana, C. et al. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterology and motility: the official journal of the European Gastrointestinal Motility Society 22, 512\u2013519, e114\u2013515, https:\/\/doi.org\/10.1111\/j.1365-2982.2009.01427.x (2010).","DOI":"10.1111\/j.1365-2982.2009.01427.x"},{"key":"21241_CR28","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/00005176-199610000-00013","volume":"23","author":"WR Treem","year":"1996","unstructured":"Treem, W. R., Ahsan, N., Kastoff, G. & Hyams, J. S. Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation. Journal of pediatric gastroenterology and nutrition 23, 280\u2013286 (1996).","journal-title":"Journal of pediatric gastroenterology and nutrition"},{"key":"21241_CR29","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.3945\/jn.109.104638","volume":"139","author":"L Peng","year":"2009","unstructured":"Peng, L., Li, Z. R., Green, R. S., Holzman, I. R. & Lin, J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. The Journal of nutrition 139, 1619\u20131625, https:\/\/doi.org\/10.3945\/jn.109.104638 (2009).","journal-title":"The Journal of nutrition"},{"key":"21241_CR30","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1017\/S0954422410000247","volume":"23","author":"P Guilloteau","year":"2010","unstructured":"Guilloteau, P. et al. From the gut to the peripheral tissues: the multiple effects of butyrate. Nutrition research reviews 23, 366\u2013384, https:\/\/doi.org\/10.1017\/S0954422410000247 (2010).","journal-title":"Nutrition research reviews"},{"key":"21241_CR31","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/MCO.0b013e32833eebe5","volume":"13","author":"K Meijer","year":"2010","unstructured":"Meijer, K., de Vos, P. & Priebe, M. G. Butyrate and other short-chain fatty acids as modulators of immunity: what relevance for health? Current opinion in clinical nutrition and metabolic care 13, 715\u2013721, https:\/\/doi.org\/10.1097\/MCO.0b013e32833eebe5 (2010).","journal-title":"Current opinion in clinical nutrition and metabolic care"},{"key":"21241_CR32","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/MCO.0b013e32835665fa","volume":"15","author":"AJ Leonel","year":"2012","unstructured":"Leonel, A. J. & Alvarez-Leite, J. I. Butyrate: implications for intestinal function. Current opinion in clinical nutrition and metabolic care 15, 474\u2013479, https:\/\/doi.org\/10.1097\/MCO.0b013e32835665fa (2012).","journal-title":"Current opinion in clinical nutrition and metabolic care"},{"key":"21241_CR33","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1053\/j.gastro.2005.03.082","volume":"128","author":"S Bourdu","year":"2005","unstructured":"Bourdu, S. et al. Rectal Instillation of Butyrate Provides a Novel Clinically Relevant Model of Noninflammatory Colonic Hypersensitivity in Rats. Gastroenterology 128, 1996\u20132008, https:\/\/doi.org\/10.1053\/j.gastro.2005.03.082 (2005).","journal-title":"Gastroenterology"},{"key":"21241_CR34","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1136\/gutjnl-2012-302260","volume":"62","author":"D Xu","year":"2013","unstructured":"Xu, D., Wu, X., Grabauskas, G. & Owyang, C. Butyrate-induced colonic hypersensitivity is mediated by mitogen-activated protein kinase activation in rat dorsal root ganglia. Gut 62, 1466\u20131474, https:\/\/doi.org\/10.1136\/gutjnl-2012-302260 (2013).","journal-title":"Gut"},{"key":"21241_CR35","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1099\/ijs.0.001792-0","volume":"59","author":"RS Gupta","year":"2009","unstructured":"Gupta, R. S. & Gao, B. Phylogenomic analyses of clostridia and identification of novel protein signatures that are specific to the genus Clostridium sensu stricto (cluster I). International journal of systematic and evolutionary microbiology 59, 285\u2013294, https:\/\/doi.org\/10.1099\/ijs.0.001792-0 (2009).","journal-title":"International journal of systematic and evolutionary microbiology"},{"key":"21241_CR36","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1053\/j.gastro.2011.07.043","volume":"141","author":"M Rajilic-Stojanovic","year":"2011","unstructured":"Rajilic-Stojanovic, M. et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 141, 1792\u20131801, https:\/\/doi.org\/10.1053\/j.gastro.2011.07.043 (2011).","journal-title":"Gastroenterology"},{"key":"21241_CR37","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.3748\/wjg.v22.i7.2219","volume":"22","author":"E Distrutti","year":"2016","unstructured":"Distrutti, E., Monaldi, L., Ricci, P. & Fiorucci, S. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. World journal of gastroenterology 22, 2219\u20132241, https:\/\/doi.org\/10.3748\/wjg.v22.i7.2219 (2016).","journal-title":"World journal of gastroenterology"},{"key":"21241_CR38","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1099\/jmm.0.028126-0","volume":"60","author":"K Ponnusamy","year":"2011","unstructured":"Ponnusamy, K., Choi, J. N., Kim, J., Lee, S. Y. & Lee, C. H. Microbial community and metabolomic comparison of irritable bowel syndrome faeces. Journal of medical microbiology 60, 817\u2013827, https:\/\/doi.org\/10.1099\/jmm.0.028126-0 (2011).","journal-title":"Journal of medical microbiology"},{"key":"21241_CR39","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.cca.2009.01.028","volume":"403","author":"A Sikander","year":"2009","unstructured":"Sikander, A., Rana, S. V. & Prasad, K. K. Role of serotonin in gastrointestinal motility and irritable bowel syndrome. Clinica chimica acta; international journal of clinical chemistry 403, 47\u201355, https:\/\/doi.org\/10.1016\/j.cca.2009.01.028 (2009).","journal-title":"Clinica chimica acta; international journal of clinical chemistry"},{"key":"21241_CR40","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1053\/j.gastro.2005.09.031","volume":"130","author":"W Atkinson","year":"2006","unstructured":"Atkinson, W., Lockhart, S., Whorwell, P. J., Keevil, B. & Houghton, L. A. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 130, 34\u201343, https:\/\/doi.org\/10.1053\/j.gastro.2005.09.031 (2006).","journal-title":"Gastroenterology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21241-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21241-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21241-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T21:27:42Z","timestamp":1671571662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-21241-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,14]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["21241"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-21241-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,14]]},"assertion":[{"value":"2 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"2964"}}